We have FLU vaccines! See Practice News
What is it: Beyfortus®is a monoclonal antibody against Respiratory Syncytial Virus (RSV) that is indicated to avoid serious RSV infections in all infants. RSV is the #1 cause of infant hospitalization and peaks in late fall thru spring. This year’s RSV season begins 10/1/2023.
Who is it recommended for? Beyfortus® is recommended by FDA, CDC, and ACIP for all infants under 9 months of age entering their first RSV season. It is advised to give as close to birth as possible for infants born during the RSV season, and at the start of the season for infants born between February and October.
How is it given? It is a single injection given in the leg. It is a long-acting, passive immunity product. It offers protection immediately and should last for 6 months (ie the duration of the RSV season). Sapphire should have doses by October 1st, 2023.
Are there side effects? As Beyfortus® creates passive immunity and is not an active vaccine, there are no expected side effects, not even fever. It has been tested and can be given with any other childhood vaccine. (read more here: www.Beyfortus.com)
We could not be happier this is available and are pleased to be able to provide early access!!
Commercial insurance is not yet providing coverage for Beyfortus®.
While we do expect it will eventually be covered, there is no timeline or guarantee of eventual coverage. RSV season begins 10/1/2023, so time is of the essence. Sapphire wants you to have access to Beyfortus® as soon as we do, without regard to your insurer’s timeline.
(If your child is insured by Medicaid, your products will available by 10/1/23 and covered right away)
If you would like Beyfortus® NOW, there are 2 options for your commercially insured infant:
Next steps for you: